Fixed-dose-rate administration of gemcitabine in cancer-bearing cats: A pilot study

Crystal L. Garnett, Teri A. Guerrero, Carlos O. Rodriguez

Research output: Contribution to journalArticle

Abstract

Gemcitabine is an antimetabolite chemotherapy agent with schedule-dependent metabolism and efficacy. The purpose of this study was to identify the fixed-dose-rate (FDR) of gemcitabine administration in cancer-bearing cats that achieved a target plasma concentration (TPC) of 10 to 20 u.M. Fifteen client-owned cats received gemcitabine infusions administered at various FDR for 1 to 6 hours. Plasma gemcitabine and dFdU (2′,2′-difluorodeoxyuridine), the major gemcitabine metabolite, were quantitated by high performance liquid chromatography. Cats treated with an FDR less than 2.5 mg/m2 per minute failed to achieve TPC, whereas cats treated with an FDR of 10 mg/m2 per minute quickly exceeded the target range. An FDR of 5 mg/m2 per minute provided the longest duration of exposure without exceeding the upper limit of the TPC. Plasma dFdU concentration mirrored plasma gemcitabine concentrations. These data suggest that in order to maintain TPC of gemcitabine in cats the FDR lies between 2.5 and 5 mg/m2 per minute. A Phase II study to evaluate efficacy and toxicity of this approach is underway.

Original languageEnglish (US)
Pages (from-to)1149-1155
Number of pages7
JournalCanadian Veterinary Journal
Volume57
Issue number11
StatePublished - Nov 1 2016

Fingerprint

gemcitabine
Cats
cats
neoplasms
dosage
Neoplasms
Antimetabolites
drug therapy
exposure duration
high performance liquid chromatography
Appointments and Schedules
metabolites
toxicity
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Garnett, C. L., Guerrero, T. A., & Rodriguez, C. O. (2016). Fixed-dose-rate administration of gemcitabine in cancer-bearing cats: A pilot study. Canadian Veterinary Journal, 57(11), 1149-1155.

Fixed-dose-rate administration of gemcitabine in cancer-bearing cats : A pilot study. / Garnett, Crystal L.; Guerrero, Teri A.; Rodriguez, Carlos O.

In: Canadian Veterinary Journal, Vol. 57, No. 11, 01.11.2016, p. 1149-1155.

Research output: Contribution to journalArticle

Garnett, CL, Guerrero, TA & Rodriguez, CO 2016, 'Fixed-dose-rate administration of gemcitabine in cancer-bearing cats: A pilot study', Canadian Veterinary Journal, vol. 57, no. 11, pp. 1149-1155.
Garnett, Crystal L. ; Guerrero, Teri A. ; Rodriguez, Carlos O. / Fixed-dose-rate administration of gemcitabine in cancer-bearing cats : A pilot study. In: Canadian Veterinary Journal. 2016 ; Vol. 57, No. 11. pp. 1149-1155.
@article{df16d6d7460b4037b6f85dfa9d39214b,
title = "Fixed-dose-rate administration of gemcitabine in cancer-bearing cats: A pilot study",
abstract = "Gemcitabine is an antimetabolite chemotherapy agent with schedule-dependent metabolism and efficacy. The purpose of this study was to identify the fixed-dose-rate (FDR) of gemcitabine administration in cancer-bearing cats that achieved a target plasma concentration (TPC) of 10 to 20 u.M. Fifteen client-owned cats received gemcitabine infusions administered at various FDR for 1 to 6 hours. Plasma gemcitabine and dFdU (2′,2′-difluorodeoxyuridine), the major gemcitabine metabolite, were quantitated by high performance liquid chromatography. Cats treated with an FDR less than 2.5 mg/m2 per minute failed to achieve TPC, whereas cats treated with an FDR of 10 mg/m2 per minute quickly exceeded the target range. An FDR of 5 mg/m2 per minute provided the longest duration of exposure without exceeding the upper limit of the TPC. Plasma dFdU concentration mirrored plasma gemcitabine concentrations. These data suggest that in order to maintain TPC of gemcitabine in cats the FDR lies between 2.5 and 5 mg/m2 per minute. A Phase II study to evaluate efficacy and toxicity of this approach is underway.",
author = "Garnett, {Crystal L.} and Guerrero, {Teri A.} and Rodriguez, {Carlos O.}",
year = "2016",
month = "11",
day = "1",
language = "English (US)",
volume = "57",
pages = "1149--1155",
journal = "Canadian Veterinary Journal",
issn = "0008-5286",
publisher = "Canadian Veterinary Medical Association",
number = "11",

}

TY - JOUR

T1 - Fixed-dose-rate administration of gemcitabine in cancer-bearing cats

T2 - A pilot study

AU - Garnett, Crystal L.

AU - Guerrero, Teri A.

AU - Rodriguez, Carlos O.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Gemcitabine is an antimetabolite chemotherapy agent with schedule-dependent metabolism and efficacy. The purpose of this study was to identify the fixed-dose-rate (FDR) of gemcitabine administration in cancer-bearing cats that achieved a target plasma concentration (TPC) of 10 to 20 u.M. Fifteen client-owned cats received gemcitabine infusions administered at various FDR for 1 to 6 hours. Plasma gemcitabine and dFdU (2′,2′-difluorodeoxyuridine), the major gemcitabine metabolite, were quantitated by high performance liquid chromatography. Cats treated with an FDR less than 2.5 mg/m2 per minute failed to achieve TPC, whereas cats treated with an FDR of 10 mg/m2 per minute quickly exceeded the target range. An FDR of 5 mg/m2 per minute provided the longest duration of exposure without exceeding the upper limit of the TPC. Plasma dFdU concentration mirrored plasma gemcitabine concentrations. These data suggest that in order to maintain TPC of gemcitabine in cats the FDR lies between 2.5 and 5 mg/m2 per minute. A Phase II study to evaluate efficacy and toxicity of this approach is underway.

AB - Gemcitabine is an antimetabolite chemotherapy agent with schedule-dependent metabolism and efficacy. The purpose of this study was to identify the fixed-dose-rate (FDR) of gemcitabine administration in cancer-bearing cats that achieved a target plasma concentration (TPC) of 10 to 20 u.M. Fifteen client-owned cats received gemcitabine infusions administered at various FDR for 1 to 6 hours. Plasma gemcitabine and dFdU (2′,2′-difluorodeoxyuridine), the major gemcitabine metabolite, were quantitated by high performance liquid chromatography. Cats treated with an FDR less than 2.5 mg/m2 per minute failed to achieve TPC, whereas cats treated with an FDR of 10 mg/m2 per minute quickly exceeded the target range. An FDR of 5 mg/m2 per minute provided the longest duration of exposure without exceeding the upper limit of the TPC. Plasma dFdU concentration mirrored plasma gemcitabine concentrations. These data suggest that in order to maintain TPC of gemcitabine in cats the FDR lies between 2.5 and 5 mg/m2 per minute. A Phase II study to evaluate efficacy and toxicity of this approach is underway.

UR - http://www.scopus.com/inward/record.url?scp=85009270167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009270167&partnerID=8YFLogxK

M3 - Article

C2 - 27807377

AN - SCOPUS:85009270167

VL - 57

SP - 1149

EP - 1155

JO - Canadian Veterinary Journal

JF - Canadian Veterinary Journal

SN - 0008-5286

IS - 11

ER -